| Date | Ticker | Price | Dir | Speaker | Thesis | Source |
|---|---|---|---|---|---|---|
| Feb 18 | LONG | The FDA aims to cut the "pre-IND" approval timeline from 520 days down to competitive levels (China is ~200 days) to bring Phase 1 trials back to the US. Reducing regulatory red tape and startup time for clinical trials lowers cash burn for early-stage biotechs and encourages domestic innovation. LONG the US biotech ecosystem. Bureaucratic inertia may prevent meaningful process changes. |